In a Phase 2 conjunctival allergy challenge study, IC 265 demonstrated the following:
IC 265: Development strategy
Scientific and clinical validation
Completed Phase 2 in Conjunctival Allergen Challenge (CAC) model as proof of concept (POC) for ocular surface inflammation
Positive POC for ocular surface activity in reducing redness and demonstrated anti-inflammatory effect
IC 265 concentrations were found well tolerated in the Phase 2 study
Formulation
Manufacturing clinical supplies for Good Manufacturing Practice (GMP)
Formulation
Open Investigational New Drug (IND) application with US FDA
Planned Phase 2 parallel-group study in dry eye patients
View other products
Connect with us